Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Oramed Pharmaceuticals Stock Down 2.3%

Shares of Oramed Pharmaceuticals stock opened at $2.15 on Friday. Oramed Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $3.09. The company has a 50 day moving average of $2.25 and a 200 day moving average of $2.31. The company has a market capitalization of $87.83 million, a P/E ratio of 19.55 and a beta of 1.65.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The firm had revenue of $2.00 million for the quarter. As a group, research analysts anticipate that Oramed Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. N.E.W. Advisory Services LLC lifted its stake in Oramed Pharmaceuticals by 52.9% during the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 6,540 shares during the last quarter. World Equity Group Inc. acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $48,000. Dimensional Fund Advisors LP lifted its position in shares of Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after buying an additional 70,190 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Oramed Pharmaceuticals in the 4th quarter valued at $550,000. Finally, Boothbay Fund Management LLC grew its position in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after buying an additional 16,857 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.